AOC3 and metabolic dysfunction-associated steatohepatitis: In various preclinical NASH models, gene knockout or pharmacological inhibition of VAP-1 can reduce oxidative stress and recruitment of inflammatory cells to the liver and attenuate liver fibrosis (Foot et al., 2013; Weston et al., 2015).